Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29600723 | 0.86 | HSD11B1 (0.37) | HSD11B1DHFRTNK2 | |
| SCHEMBL14184913 | 0.84 | HSD11B1 (0.37) | HSD11B1DHFRTNK2KDM4C | |
| SCHEMBL12642069 | 0.83 | HSD11B1 (0.34) | HSD11B1DHFR | |
| SCHEMBL2028590 | 0.81 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL16426108 | 0.79 | HSD11B1 (0.36) | HSD11B1DHFR | |
| SCHEMBL18530941 | 0.79 | LPL (0.35) | HSD11B1DHFR | |
| SCHEMBL8265696 | 0.78 | CA1 (0.43) | HSD11B1TNK2 | |
| SCHEMBL23907104 | 0.77 | DHFR (0.37) | HSD11B1DHFRTNK2KDM4C | |
| SCHEMBL1118822 | 0.77 | HSD11B1 (0.43) | HSD11B1DHFRTNK2KDM4C | |
| SCHEMBL16583636 | 0.77 | PDE10A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423176-A1 | CARBOXYLIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010123016-A1 | CARBOXYLIC ACID COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123017-A1 | TETRAZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | GPR119, GPR65, GPR55 | HSD11B1 672/4885DHFR 2932/4885TNK2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.